Navarixin clinical trials
Also written SCH 527123.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses navarixin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses navarixin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)CompletedPhase 2Merck Sharp & Dohme LLCNCT03473925Written as Navarixin
- A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)CompletedPhase 2Merck Sharp & Dohme LLCNCT00684593Written as Navarixin 10 mg
- Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)CompletedPhase 2Merck Sharp & Dohme LLCNCT00688467Written as Navarixin
- Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00632502Written as Navarixin
- Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00441701Written as Navarixin 1 mg
- Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)TerminatedPhase 2Merck Sharp & Dohme LLCNCT01006616Written as Navarixin
- Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)WithdrawnPhase 2Merck Sharp & Dohme LLCNCT01006161Written as SCH 527123
- Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01068145Written as SCH 527123
Codes
What other systems call navarixin · ClinicalTrials.gg INT002075
- UNII (FDA) 7V3BY6G538NAVARIXINConfirmed FDA, Wikidata
- Wikidata Q83117346navarixin hydrateConfirmed FDA, Wikidata
- NCI Thesaurus C156730NavarixinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7V3BY6G538 | NAVARIXIN | Confirmed FDA, Wikidata |
| Wikidata | Q83117346 | navarixin hydrate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156730 | Navarixin | One source FDA |
Also registered as navarixin anhydrous (UNII 4GMU5HUX5I).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.